https://html5-player.libsyn.com/embed/episode/id/29897358/height/90/theme/custom/thumbnail/yes/direction/forward/tdest_id/2380475/render-playlist/no/custom-color/000000/
Skills intelligence: building organisations with a skills-first approach
skills intelligencebuilding organisationsfirstapproach
https://www.unsw.edu.au/research/sprc/our-projects/national-alliance-of-capacity-building-organisations-nacbo
National Alliance of Capacity Building Organisations (NACBO) | Social Policy Research Centre - UNSW...
The project is to evaluate the National Alliance of Capacity Building Organisations (NACBO) projects.
social policy research centrenational alliancecapacity building
https://goodbear.co.uk/
Good Bear - Building websites for charities and purposeful organisations
websites for charitiesgoodbearbuildingpurposeful
https://www.jbs.cam.ac.uk/events/building-healthier-workplaces/
Building healthier workplaces: evidence-based implications for organisations and employees -...
Apr 27, 2026 - Connect with Cambridge Judge! Explore our full calendar of upcoming events, learn about our programmes and connect with world-class speakers.
healthier workplacesevidence basedfor organisationsbuildingimplications
https://research.ugent.be/web/result/project/e2946708-d8f0-4ae1-95ec-c6c370374611/organisations/vission-41s09122-active-building-blocks-for-visible-and-near-infrared-applications-on-a-silicone-nitride-interposer/en
Research Explorer - Project organisations of (41S09122, VISSION) Active Building Blocks for Visible...
Research Explorer - Organisations for research project Active Building Blocks for Visible and Near-Infrared Applications on a Silicone Nitride Interposer...
research explorerproject organisations
https://www.capgemini.com/gb-en/news/press-releases/large-pharma-organisations-to-invest-nearly-7-of-revenue-on-building-connected-cutting-edge-lab-environments-by-2025/
Large pharma organisations to invest nearly 7% of revenue on building connected, cutting-edge lab...
Mar 10, 2025 - Next-gen lab environments are now critical for innovative therapies, reduced time to market, and improved approval rates, but most are still at pilot phase